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Cell proliferationAbstract To investigate the effect of over-expression of tissue factor pathway inhibitor-2 (TFPI-2)
on the differentiation of hepatocellular carcinoma (HCC) cells (Hep3B and HepG2). The TFPI-2
recombinant adenovirus (pAd-TFPI-2) was constructed using the pAdeasy-1 vector system. Trans-
fected by pAd-TFPI-2, the cell proliferation of HCC cells was evaluated by CCK-8 assay, flow
cytometry was used to detect cell apoptosis and CD133 expression. Real-time PCR and Western
blot were used to detect the expression levels of markers of hepatocellular cancer stem cells
(CSC) and hepatocytes. The over-expression of TFPI-2 significantly suppressed cell proliferation,
induced apoptosis, and dramatically decreased the percentage of CD133 cells, which was considered
as CSC in HCC. Real-time PCR and Western blot showed that the expression of markers of CSC in
Hep3B cells and HepG2 cells infected with pAd-TFPI-2 was markedly lower than those of the con-
trol group (P< 0.05), while the expression of markers of hepatocytes was significantly increased
(P< 0.05). Hence, TFPI-2 could induce the differentiation of hepatocellular carcinoma cells into
hepatocytes, and is expected to serve as a novel way for the treatment of HCC.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma is one of the malignancies with a
high incidence in the world, and its incidence is increasing
(Forner et al., 2012; Kim and Park, 2014). Hepatocellular car-cinoma has a silent onset with no symptoms in the early stage,
while it progresses rapidly. Currently the treatment methods
for hepatocellular carcinoma are mainly hepatic resection,
hepatic transplantation, and drug therapy. However, only
10–20% of the patients with HCC can be surgically excised,
yet attended with a high frequency of recurrence (Liu et al.,
2014). Further, HCC is chemoresistant and the current drug
therapy is associated with limited efficacy. The prognosis of
HCC patients is generally poor (Altekruse et al., 2014).
Although new strategies have been applied for HCC treatment,
efficacies are still beyond satisfactory (Kozyreva et al., 2011).
Therefore, it is of immense importance to seek some new ways
for the treatment of hepatocellular carcinoma.
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as matrix-associated serine protease inhibitor (MSPI) and pla-
cental protein 5 (PP5) (Rao et al., 1995; Kisiel et al., 1994).
TFPI-2 is a kunitz-type serine proteinase inhibitor, which is
abundantly expressed in a variety of human tissues such as
liver, pancreas, skeletal and directionally secreted into the
extracellular matrix (ECM) (Miyagi et al., 1994; Sugiyama
et al., 2002; Herman et al., 2001). TFPI-2 is thought to nega-
tively regulate the enzymatic activity including matrix metallo-
proteinase (MMP), plasmin, cathepsin G, trypsin, and plasma
kallikrein (Stamenkovic, 2003; Kempaiah et al., 2007). Previ-
ous studies have suggested that the expression of TFPI-2 is
down-regulated in many malignant tumors, including breast
cancer, gastric stromal tumor, cervical cancer, gliomas and
non-small-cell lung cancer, and low expression of TFPI-2
was associated with poor prognosis in cancer patients (Wang
et al., 2014; Zhang et al., 2013; Rao et al., 2001; Rollin
et al., 2005; Xu et al., 2013).
The therapy of induced differentiation of tumors is pro-
posed in recent years, which indicates a new direction for the
treatment of hepatocellular carcinoma. Commonly used
differentiation-inducing agents are mostly substances that
might work on other malignancies. But generally speaking,
the therapy of induced differentiation of hepatocellular carci-
noma has not yet yielded satisfactory results. It has been
reported that transmembrane protease, serine 4 (TMPRSS4)
is upregulated by the silencing of TFPI-2 through aberrant
DNA methylation in non-small-cell lung cancer (Hamamoto
et al., 2015). TMPRSS4 has been shown to be an important
regulator during the epithelial-mesenchymal transition
(EMT) in human epithelial cancer cells (Li et al., 2011).
EMT is a physiological mechanism which is present during
development, including mesoderm formation and neural tube
formation (Kalluri and Weinberg, 2009). Previous studies
showed that the EMT process may facilitate the generation
of cancer cells with the mesenchymal traits needed for dissem-
ination as well as the self-renewal properties needed for initiat-
ing secondary tumors (Hollier et al., 2009). Our previous
studies indicated that TFPI-2 could not only inhibit the prolif-
eration, invasion and metastasis of Hep3B and HepG2, but
also significantly reduce the expression and secretion of
alpha-fetal protein (AFP), a maker of HCC (Xu et al., 2011).
Therefore, we hypothesize that TFPI-2 may show an effect
on inducing the differentiation of hepatocellular carcinoma
cells (HCC) into mature hepatocytes and serve as a novel
way for the treatment of hepatocellular carcinoma.
2. Materials and methods
2.1. Construction of adenoviral vectors
The sequence of TFPI-2 gene coding sequence was amplified
by PCR. The shuttle plasmid and the TFPI-2 DNA fragment
were bound using the T4DNA ligase (TaKaRa, Japan)
after the restriction enzyme digestion. The sequence was iden-
tified via DNA sequencing and restriction enzyme digestion.
The pAdtrack-cmv-TFPI-2 and the pAdEasy-1 were
co-transformed into Escherichia coli BJ5183 with backbone
vector AdEasy-1 for homologous recombination. The recom-
binant plasmid pAd-TFPI-2 digested by Pac I (Fermentas,
USA) was used to transfect Hek293 cells (Cellbank, China)by LipofectamineTM 2000 (Invitrogen, USA) for further pack-
aging and amplification of the virus.
2.2. Cell culture and transfection
Hepatoma cell lines HepG2 and Hep3B were obtained from
the American Type Culture Collection (ATCC, USA). The
cells were grown in minimum essential medium (MEM) sup-
plemented with 10% fetal bovine serum (Gibico, USA),
1.0% glutamine, 100 lg/ml streptomycin and 100 lg/ml peni-
cillin in a humidified atmosphere containing 5% CO2 at
37 C. The virus was added to the cell monolayers. Cells were
then incubated for 2 h to complete the transfection of virus
into the cells. The serum-free medium was replaced with
serum-containing medium and cells were cultured for 48 h.
2.3. RT-PCR
Cells were harvested in Trizol (TaKaRa, Japan), and total
RNA was isolated according to the manufacturer’s instruc-
tions. After the RNA was reversely transcribed into cDNA,
the change in the expression of TFPI-2 was detected using
PCR. The cDNA was synthesized from 1 lg RNA as the tem-
plate using RT-PCR kit (Takara, Japan). The original amount
of TFPI-2 and b-actin was detected via PCR with Premix Taq
(Takara, Japan). The primers were synthesized by The Beijing
Genomics Institute (BGI, China) as follows: TFPI-2 sense 50-
ATAGGATCCACATGGACCCGCTCGC-30 and antisense
50-GGCCTCGAGAAATTGCTTCTTCCGAATTTCC-30, b-
actin sense 50-GAGTCAACGGATTTGGTCGT-30 and anti-
sense 50-GACAAGCTTCCCGTTCTCAG-30. To study
TFPI-2 gene expression, the PCR was initiated by a decontam-
ination (95 C for 5 min) and denaturation step (95 C,
30 min), followed by 30 cycles at 60 C for 30 s and at 72 C
for 40 s. The level of TFPI-2 mRNA was evaluated by the ratio
of density of TFPI-2 to b-actin.
2.4. Western blot
The cells were collected at 72 h after infection. The cultures
were washed several times with phosphate-buffered saline
(PBS). Total proteins were harvested in cell lysates supple-
mented with PMSF (1 mmol/l) to inhibit the proteases. The
samples were boiled for 5 min and the proteins were separated
by sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE)
on 12% polyacrylamide gels. After electrophoresis, proteins
were transferred onto nitrocellulose membranes and blocked
with 5% non-fat milk for 2 h at 37 C. After blocking, the
membranes were incubated for 12 h at 4 C with anti TFPI-2
antibody (Santa Cruz, USA) diluted by TBST. After several
washes, the membranes were incubated horseradish peroxidase
(HRP)-conjugated sheep anti-mouse IgG secondary antibody
(Santa Cruz, USA). After washing, the blots were detected
by Odyssey Infrared Imaging System (LI-COR).
2.5. Flow cytometry analysis
Flow cytometry was used to detect the cell apoptosis and
CD133 expression. Briefly, cells (3  105/well) were seeded in
a six-well plate, and infected with adenovirus. After 72 h, cells
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level of apoptosis of cells was detected with Annexin V-PE
Apoptosis Detection Kit (Affymetrix, USA). To detect
CD133 expression in hepatoma cells, PE-conjugated
CD133/1 (Miltenyi, GER) was used as primary antibody.
Isotype-matched mouse immunoglobulin served as controls.
The cell suspension was analyzed with a FACS Caliber flow
cytometer using CellQuest software (Becton, CA).
2.6. Cell proliferation assay
To test the inhibitory effect of TFPI-2 on human hepatoma
cell proliferation, Hep3B and HepG2 cells (3  103/well) were
seeded in a 96-well plate, respectively, and cultured for 12 h.
The cells were then infected with adenovirus as described
above. Every 24 h, the cells were harvested and 100 ll cell sus-
pension was added to each well in 96-well plates for a total of
5 days. 10 ll of the CCK-8 solution (Sigma, CA) was added to
each well of the plate and incubated for 4 h at 37 C. The num-
ber of metabolically active mitochondria and viable cells was
measured colorimetrically at 450 nm. Each experiment was
repeated at least three times with each treatment given in
triplicate.
2.7. Detection of CSC markers and hepatocyte markers
Primers for these transcripts were listed in Supporting Table 1.
cDNA was synthesized with an oligo (dT) primer and M-MLV
reverse transcriptase according to a standard protocol. The
original amount of the specific transcripts was detected via
real-time PCR with a SYBR PCR Kit (TaKaRa, Japan).
The expression of specific transcripts was normalized against
that of b-actin. Western blot analysis of c-Myc and b-catenin
was performed according to the manufacturer’s instructions
(Santa Cruz, USA). After incubating with primary and sec-
ondary antibodies, the blots were detected by LI-COR.
2.8. Statistical treatment
The software SPSS 17.0 was adopted for the analysis of vari-
ous data, which were represented as mean ± standard devia-
tion (x s) for triplicate samples. Student’s t-test was used
to compare the difference between groups. A P value of
<0.05 was considered to be statistically significant.
3. Results
3.1. Identification of the recombinant adenovirus
Hep3B cells infected with recombinant adenovirus were cul-
tured for 48 h, green fluorescent protein (GFP) reached over
80%, indicating that the recombinant adenovirus could effi-
ciently infect Hep3B cells in vitro (Fig. 1A). After Ad-TFPI-
2 infected Hep3B cells for 48 h, the expression level of TFPI-
2 mRNA in Hep3B cells was detected by PCR. Quantitative
evaluation after Ad-TFPI-2 infection was normalized to that
of b-actin and revealed that increased expression of TFPI-2
mRNA was found in the Hep3B-TFPI-2 cells compared with
Hep3B-GFP (P< 0.01) (Fig. 1B). Expression of TFPI-2 pro-
tein in Hep3B-TFPI-2 cells, Hep3B-GFP and Hep3B cells,analyzed by Western blot with anti TFPI-2 antibody, was
shown in Fig. 1C. Western blot analysis for TFPI-2 protein
expression in three groups indicated TFPI-2 protein expression
was increased in Hep3B-TFPI-2 cells, as compared with those
in the control groups. We detected 3 different glycosylated iso-
forms of TFPI-2, and all 3 isoforms were upregulated by Ad-
TFPI-2 infection in Hep3B cells. These results showed that
TFPI-2 was successfully transfected into Hep3B cells.
3.2. TFPI-2 induces apoptosis in Hep3B cells
To determine the effect of TFPI-2 on cell apoptosis in HCC,
flow cytometry was performed to detect the population of
apoptotic cells in Hep3B cells. It could be observed from
Fig. 2A that up to (12.53 ± 0.36)% of Hep3B cells became
apoptotic after TFPI-2 gene delivery, while in the GFP-
infected group and un-infected group the apoptosis rate was
(2.72 ± 0.18)% and (2.33 ± 0.19)%, respectively. The differ-
ence of cell apoptosis rate in three groups had obvious statis-
tical significance (P< 0.05). These results have suggested
that TFPI-2 could induce the apoptosis of Hep3B cells.
3.3. TFPI-2 inhibits proliferation of Hep3B and HepG2 cells
As shown in Fig. 2B, the cell proliferation of Hep3B-TFPI-2
cells suppressed significantly from day 3, as compared with
those in 2 control groups (P< 0.05). There was no significant
difference between Hep3B-GFP cells and Hep3B cells
(P> 0.05). Cell proliferation in the HepG2-TFPI-2 group
was also significantly inhibited from day 4 (P< 0.05), but
not inhibited in the two control groups (P> 0.05).
3.4. TFPI-2 increases the expression of hepatocyte cell markers
The effect of TFPI-2 on the hepatocyte cell markers of Hep3B
and HepG2 cells was detected by real-time PCR. As shown in
Fig. 3, the over-expressed TFPI-2 could increase the expression
of hepatocyte markers, including 4-hydroxyphenylpyruvate
dioxygenase (HPD), cytochrome P4501a2 (CYP1a2), biliver-
din reductase (BR), phosphoenolpyruvate carboxykinase
(PEPCK), glucose-6-phosphatase (G-6-P), aldolase B
(ALDOB), glycogen synthetase 2 (GYS2) and glutamine syn-
thetase (GS). The results have suggested that TFPI-2 exhibits
effects on inducing the differentiation of hepatocellular carci-
noma cells into mature hepatic cells.
3.5. TFPI-2 reduces the expression of CSC markers
CD133 is considered to serve as targets for identifying cancer
stem cells in HCC. As shown in Fig. 4A, flow cytometry
showed that CD133+ cells accounted for (57.69 ± 2.23)% of
Hep3B cells infected with Ad-TFPI-2, significantly less than
that of Hep3B cells infected with GFP [(88.46 ± 1.25)%,
P< 0.01]. The percentage of CD133+ cells in HepG2
decreased from (57.39 ± 1.17)% to (41.64 ± 1.82)% after
infection with TFPI-2 (P< 0.05). Similarly, compared with
the control group, the expression of CD133 mRNA was signif-
icantly down-regulated in Hep3B cells and HepG2 cells
infected with Ad-TFPI-2. Furthermore, the expression of c-
Myc and b-catenin mRNA was down-regulated, which are
Figure 1 Identification of TFPI-2 mRNA and protein expression in Hep3B cells. A, 48 h after AdTFPI-2 and Ad-GFP infection, the
infection rates of Hep3B could reach more than 80% in vitro indicated by green fluorescent protein (100 ). B, The expression of TFPI-2
mRNA in Hep3B was detected by PCR. The high expression of TFPI-2 mRNA was observed in Hep3B-TFPI-2 cells. There was no
expression of TFPI-2 mRNA in Hep3B-GFP or Hep3B cells. Lane 1, DNA marker DL 2000; Lane 2, Hep3B-TFPI-2 cells; Lanes 3,
Hep3B-GFP cells; Lanes 4, Hep3B-GFP cells. C. After infection with AdTFPI-2 and Ad-GFP for 72 h in Hep3B, the total proteins were
extracted and analyzed for the expression of TFPI-2 protein with Western blot. Three different glycosylation isoforms of TFPI-2 were
detected in Hep3B-TFPI-2 cells. There was no expression of TFPI-2 protein in Hep3B-GFP or Hep3B cells. Lane 1, Hep3B-TFPI-2 cells;
Lanes 2, Hep3B-GFP cells; Lanes 3, Hep3B cells.
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maintenance of pluripotency (Fig. 4B). Western blot results
also showed that the expression of c-Myc and b-catenin pro-
teins was reduced in Hep3B cells and HepG2 cells infected with
Ad-TFPI-2 (Fig. 4C).
4. Discussion
TFPI-2, also known as placental protein (PP5), is identified as
a tumor suppressor gene (Bretz et al., 2012). As a member of
the Kunitz structure superfamily, TFPI-2 is a broad-
spectrum inhibitor of serine protease. Since the promoter of
TFPI-2 is rich in CPG islands, its expression is silenced in
many malignant tumors through epigenetic modifications,
including promoter methylation and histone deacetylation
(Dong et al., 2015; Glockner et al., 2009). In addition, the
aberrant splicing form of TFPI-2 was detected during cancer
progression, which represented an untranslated form provid-
ing another mechanism (Bretz et al., 2012). Moreover, TFPI-
2 could mediate dephosphorylation of residues outside the T-
loop of ERK, which may directly impact kinase function
(Mazalouskas et al., 2014). The ERK1/2 pathway integrates
various cytosolic signals to regulate cellular proliferation, dif-ferentiation, and apoptosis, which contributes to the formation
and development of a variety of tumors (Deng et al., 2013;
George et al., 2007).
Tumors are organized in a hierarchy of heterogeneous cell
populations with different biologic properties comprising pro-
liferating transit-amplifying cells, terminally differentiated
cells, and dying cells and that the populations consist of cancer
stem cells (CSCs). Some of the proliferating cells do not differ-
entiate into mature cells, which could continue to proliferate.
The CSCs are thought to maintain tumor cells self-renewal
capacity, high proliferation rate and are more resistant to
chemotherapy than differentiated cancer cells (Ciurea et al.,
2014; Puglisi et al., 2013). Differentiation therapy could force
hepatocellular carcinoma cells to differentiate and lose self-
renewal capacity. Cell differentiation is assumed to be regu-
lated by an informational network, including transacting fac-
tors, soluble transmitters and cell-matrix adhesion molecules.
But, to our knowledge, little is known on the role of TFPI-2
inducing differentiation in hepatocellular carcinoma.
To study the relationship between TFPI-2 and tumor cells
differentiation, we constructed the recombinant adenovirus
Ad-TFPI-2 to enable TFPI-2 to overexpress in hepatocellular
carcinoma cells, and proved that Ad-TFPI-2 could infect
Figure 2 A, Detection of the effect of TFPI-2 on the apoptosis of Hep3B cells using flow cytometry. Hep3B cells (3  105/well) were
seeded in a six-well plate. After 72 h infection with adenovirus, apoptosis cells were detected by flow cytometry. Each treatment was
performed in triplicate, and the assays were repeated at least 3 times. B, TFPI-2 suppresses hepatoma cell proliferation. The suppression
rate was significant on the third day (Hep3B) and the fourth day (HepG2), respectively, after TFPI-2 infection compared with 2 control
groups. *P< 0.05 vs 2 control groups.
Figure 3 Gene expression folds of the Ad-TFPI-2-infected group versus the Ad-GFP-infected group. TFPI-2 up-regulates expression of
hepatocyte markers in Hep3B cells and HepG2 cells. The expression of characteristic hepatocyte markers was detected by real-time PCR,
and the mRNA expression levels were normalized against b-actin. Significant increases in expression of hepatocyte markers were detected
in Hep3B cells and HepG2 cells infected by Ad-TFPI-2 including 4-hydroxyphenylpyruvate dioxygenase (HPD), cytochrome P4501a2
(CYP1a2), biliverdin reductase (BR), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G-6-P), aldolase B
(ALDOB), glycogen synthetase 2 (GYS2) and glutamine synthetase (GS). *P< 0.05, **P< 0.01 vs control group.
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levels of hepatocyte makers, CD133, c-Myc and b-catenin were
analyzed. Our data suggested that TFPI-2 induced apoptosis
and inhibited proliferation of HCC. Moreover, the over-
expression of TFPI-2 could elevate the expression of hepato-
cyte makers and reduce the expression of stemness gene.
We chose Hep3B and HepG2 for the present study because
they are certified to contain a small proportion of CSCs, and
the expression of TFPI-2 was silenced, which were able to
overexpress the TFPI-2 protein and mRNA by infecting Ad-TFPI-2. Our results demonstrated that stable expression of
TFPI-2 inhibited the cell proliferation rate 2 times in Hep3B-
TFPI-2 cells. Our findings are consistent with previous reports
asserting that the over-expression of TFPI-2 induced the apop-
tosis and inhibited proliferation of cancer cells, such as hepa-
tocellular carcinoma (Wong et al., 2007), meningioma
(Kondraganti et al., 2006) and esophageal carcinoma (Ran
et al., 2009). TFPI-2 could regulate tumor angiogenesis by
reducing synthesis of the VEGF receptor and affect the expres-
sion of several genes involved in oncogenesis, invasion and
Figure 4 TFPI-2 reduced the stemness gene expression in Hep3B cells and HepG2 cells. A, Flow cytometry analysis confirmed reduced
proportion of CD133+ cells in Hep3B and HepG2 after infection with Ad-TFPI-2 (Hep3B, P< 0.01; HepG2, P< 0.05). B, Moreover,
CD133, c-Myc and b-catenin mRNA expression was also reduced compared with the control groups. mRNA expression folds of the
TFPI-2 group versus the GFP group were shown and normalized against b-actin. C, Western blot analysis for the expression of c-Myc and
b-catenin in Ad-TFPI-2 infected Hep3B cells and HepG2 cells. Reduced expression of c-Myc and b-catenin proteins was observed in both
Hep3B and HepG2. Lane 1, Hep3B-TFPI-2 cells; Lane 2, Hep3B-GFP cells; Lanes 3, HepG2-TFPI-2 cells; Lanes 4, HepG2-GFP cells.
100 Z. Li et al.apoptosis (Chand et al., 2004). In addition, TFPI-2 could also
activate caspase-mediated, pro-apoptotic signaling pathways
and induces apoptosis (George et al., 2007). Of course, further
studies are required to investigate whether these mechanisms
are also regulated within HCC cells by TFPI-2.
Recent studies suggest that malignant tumors can be viewed
as an abnormal organ, which CSCs have escaped the normal
limits of self-renewal, giving rise to abnormally differentiated
cancer cells that contribute to tumor progression. Targeting
CSCs by inducing differentiation is an encouraging way of
therapy for HCC. CD133, also called Prominin-1, is a product
of a single-copy gene on chromosome 4 (4p15.33) in human.
Liver cancer stem cells, whose specific marker was CD133,
were isolated from liver cancer cell lines, and it was found that
these cells accounted for only a very small proportion of the
cells, while they had strong capacity in colony formation andtumorigenesis (Ma et al., 2007). CD133, as a specific surface
molecule for sorting cancer stem cells, has been identified in
colon cancer (Maria et al., 2013), hepatocellular carcinoma
(Mishra et al., 2009) and lung cancer (Kristen et al., 2014).
As one of specific markers of cancer stem cells, CD133 holds
great significance in the development and progression of
HCC. Our results revealed that the percentage of CD133+
cells was significantly decreased in both Hep3B and HepG2
cells infected with AdTFPI-2. It was reported that the expres-
sion of TFPI-2 was inversely correlated with the expression of
CD133 (Chu et al., 2015). Moreover, the expression of c-Myc
and b-catenin was also demonstrated to be down-regulated by
TFPI-2 in Hep3B and HepG2. b-catenin is one of the key
effectors responsible for transduction of the signal to the
nucleus and it triggers transcription of Wnt-specific genes
responsible for the control of cell fate decisions. EMT plays
Tissue factor pathway inhibitor-2 inducedhepatocellular carcinoma cell differentiation 101an important role during embryonic development and drives
cancer cells invasion and metastases (Thiery et al., 2009). In
transitions related to cancer progression, activating mutations
of b-catenin could enhance transcription, which might have
consequences for EMT progression. TFPI-2 could up-
regulate the expression of TMPRSS4, which plays an impor-
tant regulator during the epithelial-mesenchymal transition
(EMT) (Li et al., 2011). In the nucleus, b-catenin activates
transcription of Wnt/b-catenin-target genes such as c-myc,
which is involved in cell proliferation as well as differentiation.
Consistently, our results illustrated a list of elevated genes that
are markers for hepatocyte maturation.
5. Conclusions
We successfully constructed the recombinant adenovirus Ad-
TFPI-2 that could effectively infect HCC cells and express
TFPI-2. The overexpression of TFPI-2 can inhibit the prolifer-
ation and induce the apoptosis of HCC cells, and increase the
expressions of markers of hepatic cells while decrease those of
makers of stem cells, which indicates TFPI-2 can induce the
differentiation of hepatocellular carcinoma cells into mature
hepatic cells. However, its mechanism remains elusive and
requires further studies.
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